No new SARS-CoV-2 variant of concern has been designated by WHO or ECDC in 2026, with both agencies reporting zero VOCs currently in circulation as of June and July updates. Circulating strains like BA.3.2 (nicknamed Cicada) and XFG sublineages show notable spike mutations and some immune-escape traits but have not triggered the required thresholds for increased severity, transmissibility, or vaccine impact to warrant VOC status. Ongoing genomic surveillance through wastewater, traveler testing, and clinical samples continues to track subvariants without evidence of rapid escalation. Updated 2026-2027 vaccines target dominant JN.1 lineages, and broad population immunity from prior exposures further dampens the odds of a concerning new emergence in the remaining months before 2027. Trader consensus at 88% for “No” reflects these stable conditions and the high bar for official designation.